The BCL-6 proto-oncogene encodes a 92-to 98-kDa transcriptional repressor containing the BTB/POZ domain at its N-terminal region and the zinc ®nger domain at its C-terminal region, respectively. In the present study, we examined the function of BCL-6 by using a recombinant adenovirus expressing BCL-6 (Ax1CA-BCL-6) and the lacZ reporter gene (Ax1CA-lacZ). Viability of CV-1 and HeLa cells infected with Ax1CA-BCL-6 was markedly reduced due to apoptosis, suggesting that BCL-6-overexpression induces apoptosis in CV-1 and HeLa cells. FACS analysis revealed that BCL-6-overexpressing cells are accumulated not only at the sub-G1 but also at G2/M phase. Induction of apoptosis by BCL-6 was preceded by down-regulation of apoptosis repressors BCL-2 and BCL-X L . These results suggest that BCL-6 induces apoptosis by regulating the expression of these apoptosis-regulating genes.
Introduction
The BCL-6 gene was ®rst identi®ed on the break-point of a chromosomal translocation involving 3q27 in nonHodgkin's lymphoma (NHL) (Kerckaert et al., 1993; Ye et al., 1993; Miki et al., 1994) . Subsequent genomic Southern blot analysis of NHLs revealed that the rearrangement of the BCL-6 gene was present in 27 ± 45% of diuse large B-cell lymphomas (DLBs) and 5 ± 14% of follicular lymphomas (FLs) (Bastard et al., 1994; Lo et al., 1994; Ot et al., 1994) . The translocational break-points in these cases were located immediately 3' to the ®rst exon. Thus, the translocation is thought to cause substitution of the promoter and the ®rst exon of the BCL-6 gene for those of the translocational partner gene , resulting in deregulated expression of the chimeric transcripts which are driven by the substituted promoter. Since the translational initiation site of BCL-6 is located in the third exon, the coding domain of the BCL-6 gene is kept intact, suggesting that the promoter-substituted BCL-6 gene may express structurally normal BCL-6 protein. Furthermore, small deletions or point mutations in the ®rst exon and intron have frequently been found in DLBs and FLs (Migliazza et al., 1995) . Thus, it is suggested that these translocations and mutations of the BCL-6 gene contribute to lymphomagenesis.
The BCL-6 protein (BCL-6) is a 92-to 98-kDa nuclear phosphoprotein (Onizuka et al., 1995; Moriyama et al., 1997) containing six C-terminal zinc ®nger motifs which act as a DNA binding domain Baron et al., 1995; Seyfert et al., 1996) and an N-terminal BTB/POZ domain which is known to be important for protein-protein interactions (Bardwell and Treisman 1994; Albagli et al., 1995; Dhordain et al., 1995) . These structural features are characteristic of a transcriptional factor and indeed it has already been reported that BCL-6 may act as a transcriptional repressor Seyfert et al., 1996; Chang et al., 1996; Albagli et al, 1996; Dent et al., 1997) .
BCL-6 is maximally expressed in germinal center (GC) B cells, but its expression is very low or undetectable in the marginal zone, mantle zone B cells and plasma cells (Onizuka et al., 1995; Cattoretti et al., 1995) . Furthermore, BCL-6 is also expressed in almost all DLBs, FLs and Burkitt's lymphomas (BLs), which are thought to be derived from GC B cells (Onizuka et al., 1995 , Cattoretti et al., 1995 . In GCs, GC B cells have been believed to undergo rapid proliferation, hypermutation of the immunoglobulin (Ig) gene in the variable region, clonal selection by deletion of mutated GC B cells with low anity for antigens by apoptosis, isotype switching in centrocytes with a high anity for antigens and dierentiation into memory B cells or plasma cells (Liu et al., 1997) . These ®ndings suggest that BCL-6 plays a speci®c role in GC B cells. In the present study, to elucidate the pathological signi®cance of the deregulated expression of BCL-6, we generated a recombinant adenovirus encoding BCL-6 and analysed the phenotype of the virus-transducer cells. Using this system, we found that the BCL-6-overexpressing cells underwent apoptosis, which is preceded by downregulation of BCL-2 and BCL-X L .
adenovirus which had an lacZ-expressing unit (Ax1CA-lacZ), at various multiplicities of infection (MOI). After incubation for 48 h, the cells were stained with X-gal, the number of positively stained cells was counted, and the positivity rate (percentage infection) was calculated. As shown in Figure 1 , at a MOI of 10, 73% of CV-1 cells and 94% of HeLa cells were positive for LacZ, and at a MOI of 30, 97% of CV-1 cells and 100% of HeLa cells were positive for LacZ, indicating that this recombinant adenovirus can be transduced to almost all of the cells at a MOI of at least 30. Therefore, in the following experiments we used the recombinant adenovirus which had a BCL-6-expressing unit (Ax1CA-BCL-6) at a MOI of 30.
Adenovirus-mediated expression of BCL-6 in CV-1 and HeLa cells
To examine the expression of BCL-6 in Ax1CA-BCL-6-and Ax1CAwt-infected CV-1 cells, immunoprecipitation and immunocytochemical analyses were performed using an anti-BCL-6 antibody. BCL-6 immunoprecipitated from metabolically radiolabeled CV-1 cells that had been infected with Ax1CA-BCL-6 was detected as a S-methionine for 3 h. Subsequently, cells were lysed with RIPA buer and subjected to immunoprecipitation with an anti-BCL-6 antibody. The immunoprecipitates were resolved in 7.5% SDS ± PAGE followed by autoradiography. (b) Immunostaining of Ax1CA-BCL-6-infected CV-1 cells with the anti-BCL-6 antibody. CV-1 cells were infected with Ax1CA-BCL-6 and cultured for 48 h, ®xed with 4% paraform aldehyde for 5 min and subsequently either immunostained with anti-BCL-6 antibody (a) or stained with DAPI (b) 92 ± 98-kDa band corresponding to BCL-6, but this band was not detected in Ax1CAwt-infected cells at a MOI of 30 ( Figure 2a ). Immunocytochemistry revealed that CV-1 cells infected with Ax1CAwt were not immunoreactive for the anti-BCL-6 antibody (data not shown), while more than 90% of those infected with Ax1CA-BCL-6 at a MOI of 30 exhibited strong nuclear staining ( Figure  2b ). These results indicate that BCL-6 is highly expressed in Ax1CA-BCL-6-infected cells.
Ectopic over-expression of BCL-6 induces cell death
To clarify the phenotypic changes that occurred in BCL-6-overexpressing cells, we tried to investigate the morphology of Ax1CA-BCL-6-infected cells over the passage of time. However, cells infected with Ax1CA-BCL-6 became rounded about 48 h after infection and ®nally detached from the tissue culture dish, whereas cells infected with Ax1CAwt showed no such changes. Therefore, we analysed the time course of cell viability by MTT assay using Ax1CA-BCL-6 at a MOI of 30. The decrease in cell survival was detectable by 48 h after infection and by 72 h after infection cell survival was dramatically decreased, although some cells survived as long as 5 days after treatment (Figure 3a and b). Next, we analysed the eect of viral concentration on cell viability. As shown in Figure 3 , CV-1 and HeLa cells infected with Ax1CAwt showed no changes in viability at a MOI of 200 even 120 h after infection. In contrast, cells infected with Ax1CA-BCL-6 exhibited a decrease in viability at a MOI of 10, and this decrease paralleled the viral concentration (Figure 3c and d). These results suggest that the induced cell death was not due to cytotoxicity of the Overexpression of BCL-6 augments the subG1-and G2/ M-fractions of the cell cycle Next, to determine whether BCL-6-overexpression has an eect on the cell cycle, FACS analyses were performed. As shown in Figure 4 and Table 1 , FACS analysis of cells infected with Ax1CAwt revealed that the percentages of cells in the G1, G2/M and sub-G1 phases of the cell cycle were not changed between 0 and 96 h after infection. On the other hand, when cells were infected with Ax1CA-BCL-6, the cell cycle distribution was changed dramatically. The percentage of cells in G1 phase was reduced from 51.1% to 29.2% at 48 h after infection and the percentage of the G2/M phase was increased from 36.3 to 58.7%, suggesting that G2/M arrest had occurred in at least a fraction of the cells at 48 h after infection. In addition, at this point, few cells in the sub-G1 fraction were scored. However, during 48 ± 96 h after infection, the percentage of the sub-G1 cell fraction increased dramatically from 3.2 to 51.1% ( Figure 4 and Table 1 ). Since it is known that an increase in the sub-G1 fraction is indicative of apoptosis (Darzynkiewicz et al., 1992) , it is possible that the decrease in cell viability seen 3 days after infection (Figure 3 ) was due to apoptotic cell death.
Cell death caused by BCL-6-overexpression is due to apoptosis
To con®rm that the cell death caused by BCL-6-overexpression is due to apoptosis, we examined the morphology of cells infected with Ax1CA-BCL-6 for 96 h by staining with DAPI. The cells exhibited nuclear fragmentation and chromatin condensation which are characteristics of apoptosis ( Figure 5A,a) . DNA fragmentation was detected by electrophoresis of the genomic DNA extracted from cells overexpressing BCL-6, although this was not detectable in cells infected with Ax1CAwt ( Figure 5B ). Furthermore, the fragmented nuclei of cells infected with Ax1CA-BCL-6 were positive for staining by the TUNEL technique ( Figure 5A,b) , whereas those in cells infected with Ax1CAwt were negative (data not shown). These results, together with the data obtained by FACS analysis, indicate that the cell death caused by the adenovirus-mediated overexpression of BCL-6 is due to apoptosis.
Down-regulation of BCL-2 and BCL-X L in BCLoverexpressing CV-1 cells
To elucidate the molecular mechanism of BCL-6-mediated apoptosis, the levels of expression of apoptosis-related genes including BCL-2, BCL-X L and BAX were analysed at various times after infection with Ax1CA-BCL-6. In these experiments, the level of b-actin mRNA in cells infected with either Ax1CA-BCL-6 or Ax1CAwt was used as a control, con®rming the speci®city of action of BCL-6. As shown in Figure   Figure 4 Time course of the cell cycle distribution of CV-1 cells infected with either Ax1CA-BCL-6 or Ax1CAwt. CV-1 cells were infected with either Ax1CA-BCL-6 or Ax1CAwt at a MOI of 30 and incubated for 0 h, 48 h, 72 h and 96 h, respectively. Cells were collected and stained with propidium iodide and then analysed by FACScan to determine the cell cycle distribution. Quanti®cation of the amount of cells in each phase of the cell cycle each cell cycle is given in Down-regulation of BCL-2 and BCL-X L by BCL-6
T Yamochi et al 6, the amount of the BCL-2 transcripts decreased dramatically, and was barely detectable by 24 h after infection with Ax1CA-BCL-6. The amount of the BCL-X L transcripts also decreased, but more gradually (Figure 6a ). These levels of expression of both BCL-2 and BCL-X L were not changed by infection with Ax1CAwt ( Figure 6b ). In addition, further immunoblot analyses revealed that the amount of BCL-2 protein decreased dramatically during 48 ± 72 h after infection with Ax1CA-BCL-6, but was unchanged after infection with Ax1CAwt ( Figure 7) . Thus, downregulation of the BCL-2 after infection with Ax1CA-BCL-6 was con®rmed not only at the mRNA level but also at the protein level. On the other hand, although the amount of the bax transcripts relative to that of the b-actin transcripts increased 1.7-fold up to 36 h after infection (Figure 6a ), its up-regulation at the protein level was not signi®cant (data not shown).
Discussion
In the present study, we found that overexpression of BCL-6 induced apoptosis in CV-1 and HeLa cells. The molecular mechanisms underlying this induction of apoptosis have yet to be established. Interestingly, however, we found that a high expression of BCL-6 induced remarkable down-regulation of a survival gene, BCL-2, and moderate down-regulation of BCL-X L which is a member of the same family as BCL-2. Furthermore, slight up-regulation of bax, which is known to be an apoptosis-inducing gene, was also observed at the mRNA level, although its up-regulation at the protein level was not signi®cant. BCL-2 and Bax have been reported to homodimerize by themselves or to heterodimerize with each other, and the ratio of BCL-2 to Bax has been shown to aect cell viability (Oltvai et al., 1993) . Thus, it appears that the cooperative downregulation of BCL-2 and BCL-X L may explain, in part, the mechanism of BCL-6-mediated apoptosis in CV-1 cells. In this regard, further studies should be undertaken to clarify whether the ectopic expression of BCL-2 and/or BCL-X L can rescue the BCL-6-overexpressing cells from apoptosis. In addition, since the downregulation of BCL-2 is detectable as early as 12 h after infection and precedes the induction of apoptosis, it is unlikely that the down-regulation of BCL-2 is a secondary eect of apoptosis, although it may be important for BCL-6-induced apoptosis.
In a previous study we have demonstrated that BCL-6 is expressed in GC B cells at the highest level in human tissues, but not expressed in mantle zone B cells or marginal zone B cells (Onizuka et al., 1995) . In contrast, BCL-2 has been shown to be expressed in naive B cells and memory B cells but not in GC B cells (Martinez-Valdez et al., 1996) , indicating that BCL-6 and BCL-2 are expressed in an anti-parallel manner in human lymphoid organs. It has also been reported that the apoptosis-inducing genes, p53, fas, bax and c-myc are expressed in GC B cells but not in naive B cells or memory B cells, in a similar manner to BCL-6 (Martinez-Valdez et al., 1996) . Furthermore, BCL-X L has been reported to be expressed in GC B cells and memory B cells and to be implicated in the CD40-mediated rescue of GC B cells (Tuscano et al., 1996; Ghia et al., 1998) . Thus, we speculate that a high level of expression of BCL-6 in GC B cells may contribute to the down-regulation of BCL-2 and BCL-X L leaving the GC B cells prone to apoptosis. Consistent with this hypothesis, BCL-6 is down-regulated when murine T cell-depleted splenocytes or human peripheral blood B cells are cultured with CD40 ligand (CD40L) . Furthermore, it has been reported that the CD40-mediated signal can rescue B-cells from antigen receptor-mediated apoptosis (Tsubata et al., 1993) , and that this signal also induces BCL-2 (Liu et al., 1991; Tsubata et al., 1993) or BCL-X L (Choi et al., 1995; Ishida et al., 1995) in B cells. In addition, recent studies (Dent et al., 1997; Ye et al., 1997; Fukuda et al., 1997) have revealed that BCL-6-de®cient mice are defective in their ability to form GC, although they have a normal number of B cells. Interestingly, in spite of this inability, BCL-6-de®cient B cells can form primary follicles, dierentiate into plasma cells and even produce Ig, although its serum level is relatively low (Dent et al., 1997; Ye et al., 1997) . Ye et al. have also demonstrated that BCL-6-de®cient mice cannot produce high-anity antibodies when hyperimmunized, regardless of successive immunizations. Thus, these reports argue that BCL-6 is essential for GC formation and the anity maturation of GC B cells. Based on these ®ndings, since the induction of apoptosis is believed to be important for the anity maturation in GC B cells (Liu et al., 1997) , we speculate that BCL-6 may contribute to the anity maturation of GC B cells by inducing the down-regulation of BCL-2 and BCL-X L to prime them prone to apoptosis.
Our study also showed that overexpression of BCL-6 induces cell cycle arrest at G2/M phase. This observation suggests that BCL-6 is involved in regulation of the G2/M phase. Interestingly, we have recently found that pentoxyphilline, which is known to override the G2/M delay (Fan et al., 1995) , can partially alleviate the G2/M arrest induced by BCL-6, but does not aect the induction of apoptosis (Yamochi et al., unpublished). Thus, it seems that BCL-6-mediated apoptosis does not require cell cycle arrest at the G2/M phase.
It has been reported that BCL-6 can bind to the GAS motif, a consensus binding motif for Stat6, in the promoter of the CD23b gene and repress its transcription, suggesting that CD23 may be a target gene of BCL-6 (Dent et al., 1997) . We have recently found that the promoter of the BCL-2 gene contains sequences similar to the GAS motif (Seto et al., 1988) , and that BCL-6 can bind to these sequences in vitro (Moriyama, unpublished) , suggesting that the BCL-2 gene may also be another candidate for the transcriptional target of BCL-6. Further studies are required to con®rm this possibility. Furthermore, since our ®ndings were obtained using CV-1 and HeLa cells, it will be necessary to investigate the biological function of BCL-6 in B cells in the future study. Figure 7 Western blot analysis of the expression of BCL-2 and BCL-6 protein in Ax1CA-BCL-6-infected cells. CV-1 cells were infected with Ax1CA-BCL-6 or Ax1CAwt at a MOI of 30. Cells were then collected after 0, 48 and 72 h of incubation, and the protein extracted from Ax1CA-BCL-6-infected cells (BCL-6) or from Ax1CAwt-infected cells (vector) was subjected to Western blot analysis as described in Materials and methods
Materials and methods

Construction of replication-defective recombinant adenovirus
In accordance with the method described in detail previously (Miyake et al., 1996) , the cDNA fragment encoding the full-length BCL-6 was inserted into the Swalsite of the pAdex1CAwt cassette cosmid DNA which contains the CAG promoter (Niwa et al., 1991) , but in which the E1A, E1B and E3 genes are deleted. The resulting cassette cosmid bearing a BCL-6-expression unit was then co-transfected together with the EcoT22I-digested Ad genome tagged with a 55-kDa terminal protein (DNA-TPC) prepared from the parent adenovirus into 293 cells. In 293 cells, the recombinant adenovirus can be propagated because 293 cells express both E1A and E1B protein. A virus clone which strongly expresses BCL-6 (Ax1CA-BCL-6) and a virus clone which does not have an insert (Ax1CAwt) were isolated and propagated further for the following experiments. Subsequently, double cesium step gradient puri®cation procedure (Kanegae et al., 1994) was performed to obtain a single batch of high-titer adenoviral stock (1610 11 p.f.u./ml). The titers of the viral stocks were determined by plaque assay using 293 cells as described (Kanegae et al., 1994 (Kanegae et al., , 1995 . Finally, Southern blot analyses using the E1A region as a probe were performed to exclude the possibility of the contamination of the parent adenovirus.
Cell culture and labeling
CV-1 and HeLa cells were cultured in DMEM (Nissui) containing 10% fetal calf serum (FCS). For metabolic labeling with 35 S-methionine, cells were incubated for 4 h at 378C with 100 mCi/ml 35 S-methionine (Amersham) in methionine-free medium.
Immunocytochemistry
Cells infected with Ax1CA-BCL-6 were plated on coverslips coated with collagen type IV (Nitta gelatin) and incubated for 24 h or 48 h at 378C. The cells were ®xed for 5 min in methanol at 7208C, rinsed three times with PBS containing 0.5% Tween 20 for 5 min each, then blocked with 10% normal swine serum in PBS for 15 min, followed by incubation with rabbit anti-BCL-6 polyclonal antibody (DAKO, Japan) for 1 h at room temperature (RT). The cells were then incubated with FITC-conjugated anti-rabbit IgG antibody (TAGO) for 30 min at RT, subsequently, with 1 mg/ml DAPI for 3 min, and the coverslips were mounted using 90% glycerol in PBS. The cells were observed under a Nikon¯uorescence microscope and photographed.
Immunoprecipitation
Cells were collected by centrifugation, lysed on ice for 20 min in solubilizing buer (50 mM Tris-HCl pH 7.2, 1% NP-40, 150 mM NaCl, 50 mM b-glycerophosphate, 5 mM dithiothreitol (DTT), 1 mM Na 3 VO 4 , 0.05 mM NaF, 0.1 mM (p-amidinophenyl)methanesulfonyl¯uoride and 5 mg/ml leupeptin], and centrifuged at 15 000 r.p.m. at 48C for 20 min as described previously (Onizuka et al., 1995) . The lysates were then incubated with rabbit anti-BCL-6 polyclonal antibody (DAKO) for 1 h at 48C and the resulting immunocomplexes were adsorbed on protein GSepharose (Pharmacia), washed thoroughly with solubilizing buer and subjected to SDS ± PAGE.
Western blot analysis
Cells infected with either Ax1CA-BCL-6 or Ax1CAwt were incubated for 0 or 48 h, respectively. The cells were then collected and lysed in solubilizing buer. After centrifugation at 15 000 r.p.m. at 48C for 20 min, the protein concentrations in the supernatants were determined using a BIO-RAD Protein Assay kit (BIO-RAD). For the detection of BCL-2, 5 mg of cellular protein was subjected directly to SDS ± PAGE. For the detection of BCL-6, 500 mg of protein was ®rst subjected to immunoprecipitation as described previously (Onizuka et al., 1995) before performing SDS ± PAGE. The separated proteins were then transferred to a polyvinylidene di¯uoride (PVDF) membrane (Millipore). After blocking with 10% w/v skimmed milk in 16TBS (Tris-buered saline) at 48C for 1 h, the ®lters were incubated with the anti-BCL-2 monoclonal antibody (DAKO) or anti-BCL-6 polyclonal antibody (DAKO) for 1 h at 48C, respectively. The ®lters were washed thoroughly with 16TBS containing 0.1% v/v Tween 20 and incubated with either an alkaline phosphatase-conjugated anti-mouse IgG antibody (Promega) or an alkaline phosphatase-conjugated anti-rabbit IgG antibody (Promega) at 48C for 30 min, respectively. After washing with 16TBS containing 0.1% v/v Tween 20, the ®lters were stained with 5-bromo-4-chloro-3-indolylphosphate ptoluidine salt (BCIP) and nitroblue tetrazolium chloride (NBT) according to the manufacturer's instructions (GIBCO ± BRL).
RNA extraction and Northern blotting
Total RNA was extracted using RNAzol B (Biotecx Laboratories). The probe corresponding to the bax cDNA was prepared using the reverse transcriptase-polymerase chain reaction (RT ± PCR), as described previously (Miyashita et al., 1994) . For Northern blotting, 10 mg of total RNA was electrophoresed through 1% agarose gel containing 3% formaldehyde, and then transferred to a nylon membrane (Pall Biodyne Transfer Membrane; PALL Biosupport). The membrane was hybridized at 428C with each probe, which was labeled with 32 P-dCTP using the Ready To Go DNA labeling kit (Pharmacia) according to the manufacturer's instructions. The membrane was washed with 0.26sodium chloride/sodium citrate (SSC) containing 0.1% sodium dodecyl sulfate (SDS) at 658C three times, for 30 min each time, and autoradiographed for 12 h at 7708C with intensifying screens. The membrane was deprobed and rehybridized with a b-actin probe to ensure that equal amounts of RNA were transferred.
Cell viability assay (MTT-assay)
Cells were cultured in a 96-well tissue culture dish at a density of 5610 3 cells per each well. After culture with the recombinant virus for the indicated periods, cell viability was assessed as follows. First, 10 ml of MTT solution (5 mg/ml MTT (3-(4,5-dimethyl-thiazole-3-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) in PBS (pH 7.4)) was added to each well and cultured for 4 h. Then, 100 ml of HCl (0.04 N) diluted by isopropanol was added and mixed well. After incubation for 3 min at room temperature (RT), the optical density at 590 nM was measured with a microplate reader (Dynatec Products).
TUNEL staining
To detect apoptotic cells in situ, TUNEL staining was performed using the In Situ Apoptosis Detection Kit (Oncor). Fixation and tailing with digoxigenin-dUTP were performed according to the manufacturer's instructions. Subsequently, the cells were incubated with FITCconjugated anti-digoxigenin antibody (anti-digoxigeninuorescein, Fab fragments; Boehringer Mannheim) for 30 min at RT, washed three times with PBS, stained with 1 mg/ml DAPI for 3 min and washed twice with PBS. Finally, the coverslips were mounted using 90% glycerol in PBS, and the cells were observed under a Nikon uorescence microscope.
FACS analysis
At the indicated times after recombinant adenoviral infection, both the adherent and the¯oating cells were collected, washed in cold PBS and ®xed with 70% ethanol for 30 min. Subsequently, the cells were washed and resuspended in PBS containing 50 mg/ml each RNase A (Sigma) and propidium iodide (PI) (Sigma). The stained cells were then subjected to FACS analysis (FACScan; Becton-Dickinson) within 2 h.
